Background: Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to deformity and erectile dysfunction. Nonsurgical therapeutic options for PD are limited in efficacy and safety. Myofibroblasts are key cells in the pathogenesis of PD, and inhibition of myofibroblast transformation has been suggested as a therapeutic option. Objective: To identify potential drugs using a novel phenotypic assay and then to test them using in vitro and in vivo models of PD. Design, setting, and participants: We have developed and validated a phenotypic screening assay that measures myofibroblast transformation, by which we tested 21 compounds that were suggested to be efficacious in treating PD. The successful hits from this assay were further tested using in vitro and in vivo models of PD. Results and limitations: The new assay was able to detect transforming growth factor-b1-induced myofibroblast transformation. Using this assay, phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators (SERMs) were identified to significantly inhibit myofibroblast transformation. A PDE5i (vardenafil) and an SERM (tamoxifen) inhibited myofibroblast transformation, collagen gel contraction, and extracellular matrix production in a synergistic fashion. In a rat model of PD, the antifibrotic effect of the combination of vardenafil and tamoxifen was greater than that of each drug alone. This study is limited by not providing a molecular mechanism for the proposed synergy. Conclusions: This is the first demonstration of a synergistic activity between a PDE5i and an SERM discovered through a phenotypic screening approach. Future clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. Patient summary: This report suggests that the combination of a phosphodiesterase type 5 inhibitor and a selective oestrogen receptor modulator may be efficacious in treating Peyronie's disease in its active phase.
Introduction
Peyronie's disease (PD) is a fibrotic disorder characterised by the formation of a fibrous plaque in the connective tissue surrounding the penile erectile tissue, the tunica albuginea (TA). It is a benign condition of unknown aetiology characterised by the formation of localised fibrous plaques, resulting in a penile deformity, manifesting as a curvature, indentation, or shortening during erection. The disease has been shown to be prevalent, especially as men get older [1] , and affects quality of life, principally through pain during erection, erectile dysfunction, loss of penetrative ability during intercourse, and associated psychological stress [2, 3] . Despite the progress in understanding the pathophysiology of PD, there is currently a lack of efficacious medical therapies for PD, with surgery or collagenase injections [4] being the main treatment options. Although the surgical outcomes following penile straightening are well documented, surgery is invasive, costly, and frequently detrimental to penile size and erectile function [5] .
Myofibroblasts have the features of both fibroblasts and smooth muscle cells, and are characterised by the presence of alpha-smooth muscle actin (a-SMA)-positive cytoplasmic fibres. These actin fibres contribute to the contractile ability of these cells [6] . Although various progenitor cells for myofibroblasts have been suggested [7] , they most often differentiate from locally residing fibroblasts through normal wound healing signalling, particularly transforming growth factor-b1 (TGF-b1) [8] . Myofibroblasts have been shown to play vital and ubiquitous roles in both normal wound healing and fibrosis. Most important functions include production and remodelling of extracellular matrix (ECM) protein [6, 9] , and secretion of profibrotic and proinflammatory cytokines [9] . These cells have been shown to be present in liver [10] , lung [11] , and kidney [12] fibrosis as well as in PD plaques [13, 14] . It is therefore generally agreed that myofibroblasts play a critical role in the pathophysiology of fibrosis. Since the inhibition of myofibroblast transformation has been shown to be effective in preventing fibrosis [15] , we aimed to identify whether compounds that are suggested for the treatment of PD can inhibit myofibroblast formation using a phenotypic screening assay. Here, we report the development of such a phenotypic screening assay through which we identified two classes of drugs, phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators (SERM), which were shown to synergise in both in vitro and in vivo studies.
We first developed a phenotypic screening assay that is capable of reproducibly measuring transformation of human primary TA-derived fibroblasts to myofibroblasts in a high-throughput format. We then tested 21 compounds/drugs that have been suggested to be efficacious in in vitro, in vivo animal, and human studies of PD. We identified two classes of drugs, PDE5i and SERMs, from that screen and further tested them alone or in combination in in vitro and in vivo models of PD.
2.
Patients and methods 
Loughborough, United Kingdom) as described previously [16] . The tissue
Massachusetts, United States) containing 10% FCS (Fisher Scientific) and 1% penicillin-streptomycin (GIBCO, Invitrogen) at 37 C and 5% CO 2 , for 5-7
d. Tissue fragments were carefully removed using forceps upon outgrowth of cells. Passages 2-4 were used for the rest of the experiments.
2.2.
In-cell enzyme-linked immunosorbent assay Cambridge, United Kingdom) and a nuclear counterstain at that emits at 700 nm (1:1000; DRAQ5; Biostatus, [ 2 2 _ T D $ D I F F ] Loughborough, United Kingdom) for 1 h. The plate was scanned using an infrared imaging system (Odyssey CLx imager; LI-COR) at both 700 and 800 nm wavelengths. Briefly, 10 000 cells/well were mixed with collagen solution and DMEM with or without 10 ng/ml TGF-b1, and then plated onto 96-well plates.
Collagen gel contraction assay
Cultures were incubated for 3 d at 37 C, at 5% CO 2 , and lattices were released from the walls of the wells using a sterile spatula or needle.
Contraction of the collagen lattices was observed for 8 h and 
ECM production assay
Cells were seeded onto 96-well, optical, flat-bottom, black microplates (Nunc, Fisher Scientific) at 5 Â 10 3 cells/well. After overnight attachment, they were stimulated with or without 10 ng/ml TGF-b1 and/or
compounds for 7 d. DRAQ5 in PBS (1:1000) was added, and cells were incubated for 5 min at 37 C, 5% CO 2 , before scanning the plate to obtain nuclear staining. Cells were then lysed using ammonium hydroxide as described previously [17] , and ECM was fixed using a solution containing 
Animal treatment
The animal model for PD was first described by El-Sakka et al. [18] and modified by Bivalacqua et al. [19] . 
Assessment of erectile function
At the end of wash-off period, under ketamine (100 mg/kg) and xylazine 
Quantitative polymerase chain reaction
The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems
Foster City, California, United States) was used according to the manufacturer's instructions to transcribe RNA to cDNA. One microgram in 10 ml was added to 10 ml of the master mix for reverse transcription (RT) for a total reaction volume of 20 ml. After RT, cDNA was diluted 1:10 for quantitative polymerase chain reaction (qPCR). The Applied Biosystems TaqMan Fast Advanced Master Mix was used for qPCR.
Gene-specific primer pairs for GAPDH, beta-actin, a-SMA, elastin, and collagens I, III, and V were purchased from Applied Biosystems.
StepOnePlus Real-Time PCR System and software were used for the experiments and data analysis. Data were analysed using the 2
method for relative quantifications.
Western blot
Protein ( 
Statistical analysis
Data analysis was performed using Microsoft Excel 2013 or GraphPad performed at least in triplicate (n = 9) using samples from three patients (N = 3). Results from the nine experiments were pooled, and the mean values and standard errors of mean were used for statistical analysis.
Eight rats were used in each group in in vivo experiments. Results from the rats in each group were pooled, and the mean values and standard errors of mean were used for statistical analysis. Z factor (Z 0 ) was used to measure the statistical effect size of TGF-b1-induced myofibroblast transformation, to evaluate its reproducibility, variability, and potential use as a high-throughput screening assay. The formula for Z 0 factor is given in the Supplementary material.
Results

Development and validation of the phenotypic assay
We have isolated primary fibroblasts from the plaque and nonplaque TA of patients with PD. We also isolated primary fibroblasts from TA of patients with penile cancer as nonfibrotic controls ( Supplementary Fig. 1 ). The primary fibroblasts were similar in morphology and function (as shown by their response to TGF-b1) in all three groups: fibroblasts derived from the plaque of PD patients, fibroblasts derived from the nonplaque TA of PD patients, and fibroblasts derived from the TA of patients with penile cancer. Based on this similarity, we have utilised fibroblasts derived from the nonplaque TA of PD patients throughout this work since they would be more representative of fibroblasts that have not been exposed to a profibrotic environment. The fibroblast identity of the TA-derived cells was validated ( Supplementary Fig. 2 ). Upon exposure toTGF-b1 (10 ng/ml for 72 h), we observed a significant eight-fold increase in a-SMA expression in both mRNA and protein levels in TA-derived fibroblasts (Fig. 1) . We then developed a phenotypic screening assay in a 96-well plate format using ICE where the cell viability and a-SMA protein expression can be measured simultaneously in a reproducible manner (-Z 0 = 0.89; Fig. 1 ). The assay was further validated using vehicle control and a TGF-b1 receptor antagonist (SB505124) where the cells remained viable in up to 1% dimethyl sulphoxide and SB505124 inhibited TGF-b1-induced myofibroblast transformation in a concentrationdependent manner (IC50 = 0.6 mM; Supplementary Fig. 3 ).
Hit identification
We then tested 21 compounds/drugs (Supplementary Table 1 
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were constructed for these hits, which yielded inverse sigmoid curves with an upper and a lower plateau without affecting the cell viability (Fig. 2) . The following molecules were used to investigate the two classes of drugs: vardenafil, sildenafil, and tadalafil as PDE5i (IC 50 = 30, 15, and 3.5 mM, respectively), and tamoxifen and raloxifene as SERMs (IC 50 = 11.9 and 7 mM, respectively). When a PDE5i
(vardenafil) and [ 3 9 _ T D $ D I F F ] a SERM (tamoxifen) were tested in combination, a synergy between the two drugs became apparent (the observed inhibition was greater than the arithmetic sum of each; Fig. 2 and Supplementary Table 2 ).
Functional assays
The two classes of drugs were then tested in functional assays. Firstly, we tested their efficacy in inhibiting collagen gel contraction as a measure of myofibroblast contractilitya characteristic function of myofibroblasts, which separates them from fibroblasts. Collagen gels were loaded with fibroblasts, and contraction was measured after stimulation with TGF-b1 as described before [20, 21] . Both vardenafil and tamoxifen inhibited TGF-b1-induced contraction of collagen at concentrations of 10 and 1 mM, respectively (Fig. 3 ). Secondly, we tested the drugs' efficacy in inhibiting ECM protein production, which is again one of the critical characteristic functions of myofibroblasts. Again, both vardenafil and tamoxifen inhibited TGF-b1-induced ECM protein production (collagens I, III, and V and fibronectin;
IC 50 = 23, 17, 23, and 44 mM for vardenafil, and 7, 5.3, 6.7, and 1.6 mM for tamoxifen, respectively; Fig. 4 ).
In vivo testing of the two hits
To elucidate whether the drugs could also prevent fibrosis in vivo, they were taken further to be tested in an animal model for PD. Five weeks after TGF-b1 injection into the rat TA, with or without treatment with vardenafil, tamoxifen, or their combination, the rats were subjected to erectile function measurement (ICP measurement) before harvest- SERMs tamoxifen and raloxifen on TGF-b1-induced myofibroblast transformation. Cells derived from TA tissue were exposed to a range of concentrations of PDE5i between 0.03 and 100 mM in coincubation with 10 ng/ml TGF-b1 for 72 h. Data points were plotted as average AE SEM of the percentage of maximum response of the a-SMA/DNA staining ratio (N = 3; n = 9). PDE5i = phosphodiesterase type 5 inhibitors; SEM = standard error of the mean; SERM = selective oestrogen receptor modulator; TGF-b1 = transforming growth factor-b1.
ing the penis for molecular analysis. The ICP measurement revealed that TGF-b1 injection led to a decrease in erectile function by 55%, which was prevented in all treatment groups. Treatment groups showed no significant differences in ICP compared with the vehicle-injected group (Fig. 5) . Subsequent mRNA expression analysis of the penile tissue harvested from the rats showed that expression of collagens I, III, and V were significantly upregulated in the TGF-b1 injection group, but not in the vehicle or treated groups. Treatment with vardenafil or tamoxifen therefore prevented upregulation of TGF-b1-induced increase in collagen expression. Interestingly, the combination of vardenafil and tamoxifen acted synergistically on the downregulation of elastin (Fig. 5) . The formation of fibrosis in response to TGF-b1 injection into the penis was further confirmed by measuring a-SMA in the corpus cavernosum (as a measure of loss of smooth muscle mass due to fibrotic tissue) using Western blot and immunohistochemistry. The results showed a significant loss of smooth muscle, which was prevented in the treatment groups (Fig. 5) . Furthermore, immunohistochemistry using haematoxylin and eosin and Masson's Trichrome staining showed increased infiltration of inflammatory cells, formation of fibrosis, and loss of smooth muscle in the TGF-b1-injected group, effects that were prevented in the treatment groups (Fig. 6) .
[
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Fig. 3 -Effect of compounds on TGF-b1-induced myofibroblast collagen contraction in fibroblast-populated collagen lattices (FPCLs). (A)
Representation of the contraction of the fibroblast-populated collagen lattices. Top row: example for no contraction after release. Bottom row: example for uniform contraction after release from the wall of the well. FPCLs were exposed to (B) 10 ng/ml TGF-b1 and various concentrations of tamoxifen or (C) vardenafil. FPCLs were released after 72 h and contraction was observed for 8 h. Data were presented as percentage of maximum collagen contraction compared with vehicle control (DMSO) in cells exposed to tamoxifen/vardenafil. Data points were plotted as mean AE SEM (N = 3; n = 9). DMSO = dimethyl sulphoxide; SEM = standard error of the mean; TGF-b1 = transforming growth factor-b1.* p < 0.05 versus vehicle control at the same time point. Fig. 4 -Effect of compounds on TGF-b1-induced myofibroblast ECM production. Cells derived from TA tissue were exposed to a range of concentrations of vardenafil, tamoxifen, or SB505124 in coincubation with 10 ng/ml TGF-b1 for 7 d. ECM was stained for (A) collagen I (Col I), (B) collagen III (Col III), (C) collagen V (Col V), and (D) fibronectin after cell lysis. Data points were plotted as average AE SEM of the percentage of maximum response of protein/prelysis DNA staining ratio (N = 3; n = 9). ECM = extracellular matrix; SEM = standard error of the mean; TA = tunica albuginea; TGFb1 = transforming growth factor-b1. 
4.
Discussion
In contrast to the single-target approach, phenotypic screening seeks to find compounds that target a phenotype rather than a single molecular target. In this case, we have chosen transformation of fibroblasts to myofibroblasts as the target phenotype and developed an assay that can quantify inhibition of myofibroblast transformation in a reproducible manner. Using this assay, we then tested 21 compounds/drugs that have been suggested as potentially antifibrotic agents. Among this cohort, only two groups were able to inhibit myofibroblast transfor- mation: PDE5i and SERMs. When applied together, these two classes showed synergistic activity both in vitro and in vivo.
To our knowledge, this is the first study to show a synergy between PDE5i and SERMs. PDE5i have previously been suggested to be effective antifibrotic agents in vitro using TA-derived fibroblasts [22] . This was further confirmed in an animal model for PD with long-term vardenafil treatment [23, 24] . Furthermore, in vivo studies led to PDE5i being proposed as a potential treatment for other fibrotic disorders such as muscle fibrosis in a Duchenne muscular dystrophy mouse model [25] , and for the prevention of cardiac fibrosis and its underlying cardiac fibroblast activation [26] . Tamoxifen has been shown to be effective in animal models for renal tubulointerstitial fibrosis and periportal hepatic fibrosis [27, 28] . The antimyofibroblast effect has also been reported in models utilising TGF-b1-mediated activation of primary human dermal and breast fibroblasts [29] . Previous research suggested that the effect of tamoxifen on fibroblast-mediated collagen contraction is due either to downregulation of TGF-b2 [30] or a change in the morphology of fibroblasts [31] . Oestradiol has been shown to inhibit transformation of TA-derived fibroblast to myofibroblasts [32] . However, [ 4 0 _ T D $ D I F F ] no previous study has investigated the effect of tamoxifen in an animal model of PD.
Previous clinical studies have shown mixed results using PDE5i and SERMs [33] [34] [35] [36] [37] . An open-label single-arm study with tamoxifen showed a positive effect [33] , while a later placebo-controlled study showed no effect with tamoxifen [34] . However, the open-label study noted that tamoxifen showed some improvement in patients with early PD [33] , while all the patients in the latter study were in the late phase of the disease [34] . Similarly, in studies with PDE5i, the results have been mixed [35] [36] [37] . This is not surprising since the drugs were tested on patients with established plaque-fibrotic tissue. Our results suggest that PDE5i or SERMs inhibit myofibroblast transformation and ECM production; they would not be able to reverse the established/preformed fibrosis. We are therefore proposing that the combination of PDE5i and SERMs will inhibit myofibroblast transformation, thereby leading to new fibrosis formation, and prevent new plaque formation.
We believe that more and more men are presenting at early stages of the disease, as there are now better information resources and access to healthcare to have symptoms investigated. Indeed, others have reported that 30-40% of patients present with progressing deformity [38] [39] [40] . This drug combination may be more effective in patients in the acute phase where penile pain or the onset of a nodule would be an indication for referral. This will be an area for patient and primary care education.
The doses of vardenafil and tamoxifen used in our animal model are representative of their clinical doses: tamoxifen 20 mg twice daily and vardenafil 20 mg daily (please see the Supplementary material that explains the rationale behind the dose selection). This study is limited by not providing a mechanism of action for the proposed synergistic effect of the drugs, something that is currently being investigated. The number of compounds/drugs that have been screened also limits the study; other SERMs that are used in treatment of male fertility would be very interesting to test. A larger phenotypic screening campaign is planned, hopefully providing us with more hits that might reveal new treatment strategies not only for PD but also for fibrosis in general.
Another limitation to the study is that the drugs were tested in only one of the several animal PD models [41] . Although TGF-b1 injection model is most widely used, it may not necessarily be the most clinically relevant animal model; for example, it does not develop curvature of the penis. Further studies are required to test this combination in other animal models of PD.
Conclusions
In summary, this is the first study to demonstrate a synergistic antifibrotic effect of a combination of PDE5i and SERMs in in vitro and in vivo disease models. Future prospective clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. We also envisage that the combination will be more efficacious than using either of the drugs as a monotherapy. We will be investigating such a combination in men with early PD in the near future. These results are likely to lead to further research into the interaction between the two pathways and development of novel therapeutic approaches for the prevention and/or treatment of other fibrotic diseases.
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